For instance, in non-small cell lung cancer (NSCLC), the presence of EGFR mutations or ALK rearrangements has successfully guided the use of targeted therapies, dramatically improving outcomes (41, 42). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.